Obesity is related to a higher inflammatory responsive state of circulating cells after stimulation of toll like receptor 2 and 4.

Similar documents
Toll Like Receptor 2 and 4 stimulation elicits an enhanced inflammatory response in human obese patients with atherosclerosis.

Subclinical inflammation and peripheral artery disease. Luigi M Biasucci, M.D. Institute of Cardiology Catholic University Rome, ITALY

THE COMPLEX RELATION BETWEEN VULNERABILITY AND ISCHEMIA a paradigm shift

Co-stimulation with IGF-1 and TLR ligands induces a pro-inflammatory response in PBMCs via activation of the MAPK pathway

Declaration of conflict of interest. Dominique de Kleijn is founder of a UMC Utrecht spin-off biomarker company Cavadis BV

JUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study

John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam

Oscar L. Lopez, M.D. Departments of Neurology and Psychiatry Alzheimer s Disease Research Center University of Pittsburgh School of Medicine

Novel Markers of Arterial Dysfunction

Cho et al., 2009 Journal of Cardiology (2009), 54:

ESC Congress 2011 SIMULTANEOUS HYBRID REVASCULARIZATION OF CAROTID AND CORONARY DISEASE INITIAL RESULTS OF A NEW THERAPEUTIC APPROACH

Center of Cardiovascular Disease Research, The People s Hospital of Gansu Province, Lanzhou, Gansu, China. 2

Joshua A. Beckman, MD. Brigham and Women s Hospital

Benefit of Performing PCI Based on FFR

VENOUS THROMBOEMBOLISM AND CORONARY ARTERY DISEASE: IS THERE A LINK?

High-sensitivity Troponin T Predicts Recurrent Cardiovascular Events in Patients with Stable Coronary Heart Disease: KAROLA Study 8 Year FU

Patient characteristics Intervention Comparison Length of followup

Hans Strijdom SA Heart Meeting November 2017

Inflammation, rheumatoid arthritis and cardiovascular disease

Predictor Value Cytokines for Recurrence of. Arrhythmia in Patients with Coronary Heart. Disease Combined Hypertension and Persistent

Intracellular MHC class II molecules promote TLR-triggered innate. immune responses by maintaining Btk activation

Inflammation as A Target for Therapy. Focus on Residual Inflammatory Risk

Inflammation and and Heart Heart Disease in Women Inflammation and Heart Disease

ROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret

Supplementary Online Content

Long-term prognostic value of N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) changes within one year in patients with coronary heart disease

PATIENTS AND METHODS:

Impact of coronary atherosclerotic burden on clinical presentation and prognosis of patients with coronary artery disease

Unprotected LM intervention

Novel function of NADPH oxidase in atherosclerosis. Yun Soo Bae Department of Life Science Ewha Womans University

Division of Cardiovascular Medicine, Jichi Medical University Saitama Medical Center, Japan

Macrovascular Disease in Diabetes

Lp(a) Ready for prime time? E Stroes AMC

TD-BF01: Innate immunity to microorganisms

Intervention: How and to which extent is technology helping us?

The Clinical Unmet need in the patient with Diabetes and ACS

A Comparative Study on the Effect of Ranolazine and Ivabradine on High Sensitivity C - reactive protein In Cardiac Patients

Since 1980, obesity has more than doubled worldwide, and in 2008 over 1.5 billion adults aged 20 years were overweight.

Review of guidelines for management of dyslipidemia in diabetic patients

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines

Stable Ischemic Heart Disease. Ivan Anderson, MD RIHVH Cardiology

Endothelial dysfunction and subclinical atherosclerosis in HIV/HCV- coinfected patients in the Lower Silesia Region, Poland

and Restenosis Yangsoo Jang, MD, PhD. Yonsei University College of Medicine

Rikshospitalet, University of Oslo

ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions

Treatment of Cardiovascular Risk Factors. Kevin M Hayes D.O. F.A.C.C. First Coast Heart and Vascular Center

Atherosclerotic Plaque Biomarkers: Beyond the Horizon of the Vulnerable Plaque

FEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

Cardiovascular disease and diabetes Vascular harmony

THE CARDIOVASCULAR INFLAMMATORY CONTINUUM DR AB MAHARAJ

Supplementary Table S1: Proportion of missing values presents in the original dataset

ClinicalTrials.gov Identifier: NCT Sponsor/company: Sanofi-Aventis. Date: 08/02/ 2008

All biomarkers at higher level in HIV group

Ischemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010

surtout qui n est PAS à risque?

Heart Failure and COPD: Common Partners, Common Problems. Nat Hawkins Liverpool Heart and Chest Hospital

Quality Measures MIPS CV Specific

Young high risk patients the role of statins Dr. Mohamed Jeilan

Value of cardiac rehabilitation Prof. Dr. L Vanhees

Journal of Cardiovascular Emergencies 2016;2(1):11-18 DOI: /jce

Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel

alveolar macrophages (AMs) after 24 hours of in vitro culture in complete medium

Epicardial fat volume as a predictor of coronary vulnerable plaques using cardiac computed tomography in the patients with zero calcium score

Correlation of novel cardiac marker

Term-End Examination December, 2009 MCC-006 : CARDIOVASCULAR EPIDEMIOLOGY

The presenter does not have any potential conflicts of interest to disclose

Patient referral for elective coronary angiography: challenging the current strategy

ASSOCIATION BETWEEN CARDIOVASCULAR DISEASE & CONTEMPORARILY USED PROTEASE INHIBITORS

C-reactive protein: a marker or a player?

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome

The New Era of Wellness. The Science of Inflammation. Inflammation and Interdisciplinary Care. The Immune System. Periodontal Biofilms + - 3/11/2014

EUROPEAN SURVEY OF CARDIOVASCULAR DISEASE PREVENTION AND DIABETES EUROASPIRE IV. GUY DE BACKER Ghent University,Belgium

BioRemarkable Symposium

Decreased Inflammatory Markers in Diabetic Patients with Angiographically Proved Coronary Artery Disease after 18 Months of Statins Therapy

FFR vs. icecg in Coronary Bifurcations (FIESTA) - preliminary results. Dobrin Vassilev MD, PhD National Heart Hospital Sofia, Bulgaria

STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION

Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture

Inflammation promotes rupture of atherosclerotic plaques

Supplementary Appendix

the high CVD risk smoker

Omics and coronary atherosclerosis

Serial changes in plasma levels of cytokines in patients with coronary artery disease

The 10 th International & 15 th National Congress on Quality Improvement in Clinical Laboratories

Catechins Green Tea Clones GMB4 Inhibit Inflammation Process of Atherosclerosis Through Decreasing TNF-Α Levels. *

Integrin CD11b negatively regulates TLR-triggered inflammatory responses by. activating Syk and promoting MyD88 and TRIF degradation via cbl-b

Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.

A Normal Reference Coronary Flow Reserve is Associated With a Lower Mortality in Patients With Stable Coronary Artery Disease

Beyond LDL-Cholesterol

Supplement materials:

Low grade inflammation and cardiovascular disease

Oral Disease as a Risk Factor for Acute Coronary Syndrome Single Center Experience

Managing Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures

?Who binds to it. ? Who binds these inflammatory proteins RAGE SUGAR-FREE GLYCOBIOLOGY INFLAMMATION. BASIC SCIENCE?sugar chain structure

Incidence and Predictors of Stent Thrombosis after Percutaneous Coronary Intervention in Acute Myocardial Infarction

CLINICAL OUTCOME Vs SURROGATE MARKER

Outcome of elderly patients with severe but asymptomatic aortic stenosis

DUKECATHR Dataset Dictionary

Cardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center

Transcription:

Toll Like Receptor Response and traditional risk factors for atherosclerosis: Obesity is related to a higher inflammatory responsive state of circulating cells after stimulation of toll like receptor 2 and 4. V.P.W. Scholtes Experimental Laboratory Cardiology University Medical Center Utrecht The Netherlands ESC Congress, Stockholm 21 Adipose tissue and inflammation

Atherosclerosis and inflammation Adapted from Obesity, inflammation, and atherosclerosis Viviane Z. Rocha and Peter Libby Nat. Rev. Cardiol. 6, 399 49 (29)

Toll Like Receptor and inflammation Ligand Toll Like Receptor TNF-α IL-6 NF-κB DNA transcription

Toll like Receptor Response 1 μl of blood + 1 μl of LPS 1 μl of blood + 1 μl of P3C TLR4 monocyte monocyte TLR2 cytokines ELISA: TNF-alpha

TLR response: clinical perspective (1) Enhanced response of blood monocytes to in vitro LPS challenge in patients with recurrent unstable angina, Liuzzo Circulation 21;13;2236-2241

TLR response: clinical perspective (2) Monocyte toll-like receptor 2 and 4 responses and expression following PCI. Asocation with lesion stenosis and fractional flow reserve D Versteeg Heart 28 94: 77-776

Research question Are traditional risk factors and obesity associated with an altered Toll Like Receptor response?

Obesity and inflammation Inflammatory disorder Adapted from Obesity, inflammation, and atherosclerosis Viviane Z. Rocha and Peter Libby Nat. Rev. Cardiol. 6, 399 49 (29)

Methods Cohort 1 (PCI cohort) 1 Patients scheduled for Percutaneous Coronary Intervention Cohort 2 (CEA cohort) 113 Patients scheduled for Carotid Artery Endarterectomy Exclusion of: patients with an acute Myocardial infarction patients with a chronic inflammatory disease (corticosteroid use)

Clinical Characteristics PCI cohort CEA cohort parameter 78 patients 15 patients sex / 56 / 22 73 / 35 age median [IQR] 62,5 [53 7] 7,7 [63 78] BMI median [IQR] 26.9 [24.6 34.9] 26.4 [24.2 29.5] BMI > 25 n (%) 41(73%) 14(64%) 45(66%) 23(68%) smoking n (%) 5 (6%) 27 (25%) hypertension n (%) 52 (67%) 88 (84%) diabetes n (%) 16 (21%) 21 (2%) hypercholesteremia n (%) 72 (92%) 84 (8%) family history of CVD n (%) 41 (53%) 28 (27%)

TNF-alpha ng/ml TNF-alpha ng/ml Risk factors and TLR response CEA cohort PCI cohort 1 8 TLR 2 1 8 6 6 4 4 2 2 yes (52) no (26) yes (88) no (17) yes (16) no (62) yes (21) no (84) Hypertension Diabetes

TNF-alpha ng/ml TNF-alpha ng/ml Risk factors and TLR response PCI cohort CEA cohort 1 8 TLR 2 1 8 6 6 4 4 2 2 yes (72) no (6) yes (84) no (21) Hypercholesterolemia yes (41) no (37) yes (28) no (59) Family History of CVD

TNF-alpha pg/ml TNF-alpha pg/ml Smoking and TLR response PCI cohort CEA cohort 1 TLR 2 1 p =.13 TLR 4 5 5 no (73) yes (5) no (79) yes (26) no (73) yes (5) no (79) yes (26)

TNF-alpha pg/ml TNF-alpha pg/ml BMI and TLR response PCI cohort CEA cohort p =.4 TLR 2 1 p =.41 TLR 4 1 p =.254 p =.17 5 5 < 25 (37) > 25 (68) < 25 (23) > 25 (55) < 25 (37) > 25 (68) < 25 (23) > 25 (55)

cd11b expression (mean fluorescence) cd11b expression (mean fluorescence) BMI and inflammation: Cd11b expression on monocytes 8 Study 1 p =.6 3 p =.72 Study 2 6 2 4 2 1 cd11b < 25 (13) 25-3 (21) > 3 (9) BMI group cd11b < 25 (24) 25-3 (29) > 3 (11) BMI group

hscrp serum level mg/l BMI and inflammation: hscrp levels (study 1) 15 Study 1 p =.4 1 5 < 25 (23) 25-3 (31) > 3 (24) hscrp BMI group

Conclusion Obesity was the only risk factor for CVD that was positively associated with an altered TLR response We observed a trend towards lower levels of TNF-alpha for patients who were active smokers The enhanced systemic inflammatory state in obese patients was also reflected in: - elevated levels of hscrp - and increased expression of the activation marker cd11b on monocytes.

Acknowledgements Experimental Laboratory Cardiology Prof. G. Pasterkamp Prof DPV de Kleijn dr I Hoefer dr JK van Keulen dr DIK Versteeg EHAM Elsenberg Department of Cardiology Prof DA Doevedans dr PR Stella Department of Vascular Surgery Prof FL Moll dr GJ de Borst dr J.A. van Herwaarden dr R.J. Toorop Department of Vascular Surgery dr JPPM de Vries dr H.D.W.M. Van de Pavoordt dr J. Wille drs R.H. van de Mortel dr B.A.N. Verhoeven Department of Microbiology dr G.T. Rijkers mail: vscholt2@umcutrecht.nl

Extra figures

Smoking and Attenuation of TLR response Tobacco Smoking Inhibits Expression of Proinflammatory Cytokines and Activation of IL-1R-Associated Kinase, p38, and NF- {kappa}b in Alveolar Macrophages Stimulated with TLR2 and TLR4 Agonists Haiyan Chen, Mark J. Cowan, Jeffrey D. Hasday, Stefanie N. Vogel and Andrei E. Medvedev J. Immunol. 27;179;697-616

cd11b expression (mean fluorescence) cd11b expression (mean fluorescence) Very obese patients and lower TLR responsiveness 8 Study 1 p =.6 3 p =.72 Study 2 6 2 4 2 1 cd11b < 25 (13) 25-3 (21) > 3 (9) BMI group cd11b < 25 (24) 25-3 (29) > 3 (11) BMI group

TNF-alpha pg/ml TNF-alpha pg/ml TNF-alpha pg/ml TNF-alpha pg/ml Very obese patients have a lower TLR response 15 Study 1 6A p =.6 1 Study 1 6B p =.71 1 5 5 6 < 25 (23) 25-3 (31) > 3 (24) P3C5 (TLR2) Study 2 6C BMI group p =.6 6 < 25 (23) 25-3 (31) > 3 (24) LPS1 (TLR4) Study 2 6D BMI group p =.11 4 4 2 2 < 25 (37) 25-3 (44) > 3 (24) P3C5 (TLR2) BMI group < 25 (37) 25-3 (44) > 3 (24) LPS1 BMI group

TNF-alpha pg/ml TNF-alpha pg/ml BMI and TLR response 2 study 1 1 study 2 15 1 5 5 2 25 3 35 4 BMI 2 25 3 35 4 BMI

PCI cohort CEA cohort TLR2 stimulation present not present present not present Hypertension (26) 11 [3 35] (52) 18 [8 5] (88) 12 [6 22] (17) 14 [7 25] Diabetes (16) 1 [ 26] (62) 14 [6 44] (21) 12 [7 2] (84) 12 [6 25] Hypercholesterolemia (72) 12 [4 42] (6) 23 [8 4] (84) 11 [6 21] (21) 15 [9 32] Family history of heart disease < 6 years (41) 15 [6 46] (37) 11 [3 36] (28) 11 [7 32] (59) 12 [6 19] BMI ( BMI < 25 / BMI > 25) (55) 17 [8 49] (23) 7 [2 19] (37) 9 [6 16] (68) 14 [7 28] Smoking (yes / no) (5) 8 [2 22] (73) 13 [5 43] (26) 11 [6 2] (79) 12 [7 25] TLR4 stimulation present not present present not present Hypertension (26) 355 [178 565] (52) 246 [18 582] (88) 173 [99-296] (17) 245 [152-384] Diabetes (16) 246 [155 347] (62) 363 [182 587] (21) 196 [112 271] (84) 185 [13 315] Hypercholesterolemia (72) 36 [178 561] (6) 35 [27 694] (84) 185 [13 3] (21) 22 [146 329] Family history of heart disease < 6 years (41) 273 [177 555] (37) 359 [22 578] (28) 216 [95 336] (59) 165 [18 297] BMI ( BMI < 25 / BMI > 25) (55) 364 [196 599] (23) 219 [175 362] (37) 154 [15 261] (68) 29 [112 336] Smoking (yes / no) (5) 15 [7 231] (73) 353 [191 573] (26) 26 [125-312] (79) 181 [18-3]